Medicare Benefits Schedule - Item 73429

Genetic testing (including characterisation of single nucleotide variants, structural variants, fusions and copy number alterations) in a single gene panel, requested by a specialist or consultant physician, for a patient with clinical or laboratory evidence of a glioma, glioneuronal tumour or glioblastoma, to aid diagnosis and classification of the relevant tumour, including assessments of at least the following kinds:

(a) IDH1, IDH2—variant testing;

(b) 1p/19q—co‑deletion assessment;

(c) H3F3A—variant status;

(d) TERT—promoter variant status;

(e) EGFR—amplification;

(f) CDKN2A/B—deletion;

(g) BRAF—variants

Applicable to one test per diagnostic episode

Fee: $887.90 Benefit: 75% = $665.95 85% = $789.20

(See para PN.7.10 of explanatory notes to this Category)

• Previous - Item 73428
• Next - Item 73430

Testing should include, but not be restricted to, genes described in the current World Health Organization Classification of Tumours. 

Related Items: 73429